Cell therapy in ischemic heart and vascular diseases with endothelial progenitor cells (EPCs) or mesenchymal stem cells has shown some promise. Several factors, however, including low cell viability, poor cell adhesion, limited migration, low retention, poor cell differentiation, and thus low engraftment and poor long-term survival and function of transplanted cells, have limited the clinical efficacy and translation of cell therapy to the regeneration of ischemic and injured myocardium. Because necessity is the mother of invention, an interdisciplinary group of investigators designed a biomaterial with injectable hydrogel for a minimally invasive approach to deliver cells and therapeutics to a specific tissue site in sustainable manner.
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Cell therapy in ischemic heart and vascular diseases with endothelial progenitor cells (EPCs) or mesenchymal stem cells has shown some promise. Several factors, however, including low cell viability, poor cell adhesion, limited migration, low retention, poor cell differentiation, and thus low engraftment and poor long-term survival and function of transplanted cells, have limited the clinical efficacy and translation of cell therapy to the regeneration of ischemic and injured myocardium. Because necessity is the mother of invention, an interdisciplinary group of investigators designed a biomaterial with injectable hydrogel for a minimally invasive approach to deliver cells and therapeutics to a specific tissue site in sustainable manner. [1] [2] [3] There are many challenges in such an approach, however, depending on different clinical conditions and the tissue site, that require serious consideration in the attempt to enhance cell survival. No single hydrogel is optimal, and even within a hydrogel many factors, such as the selection of the size and biomechanical properties, are critical to enhancing long-term retention, differentiation, and function of transplanted cells. Indeed, injectable shear-thinning hydrogels were developed by crosslinking adamantine and b-cyclodextrin-modified hyaluronic acid and encapsulating them with EPCs with weak bonding, so that the shear stress developed during injection decreases viscosity and thus protects the EPCs from membrane-damaging forces, improving cell survival and delivery and thus the engraftment to the infarcted site in the myocardium. 4, 5 This promising approach has been used by Gaffey and colleagues, 1 as reported in their earlier publication, to stabilize cardiac function after ischemia. These same investigarors 6 report in this issue of the Journal a similar approach examining the regional biomechanics by means of speckle tracking, showing dynamic mechanical properties of ventricular myocardium after administration of hyaluronic acid shear-thinning hydrogel containing EPCs and comparing them with those seen with shear-thinning hydrogel alone, EPCs alone, and phosphate-buffered saline solution in a rat model of myocardial infarction. It is indeed interesting to see a significantly increased engraftment and retention of the EPCs within the myocardium, along with improvement in left ventricular ejection fraction and positive and higher myocardial strain, in the shearthinning hydrogel containing EPCs group than in the other experimental groups. These findings support the beneficial effect of injectable shear-thinning hyaluronic acid hydrogel containing EPCs to reduce dynamic stiffness and adverse myocardial remodeling, thus improving left ventricular function, after myocardial infarction in a rat model. These findings of Gaffey and colleagues 6 are indeed promising, but they warrant further investigation in clinically relevant experimental models, such as swine, before this treatment is considered a clinically feasible approach for potential clinical trials. In addition, it is critical to investigate the underlying cellular and molecular mechanisms. Indeed, hyaluronic acid (or hyaluronan), which is a naturally occurring polysaccharide in several tissues, including the heart, is released on injury for tissue repair and binds to CD44 present on many structural and immune cells. 7 For the use of hydrogels in regenerative therapies, however, molecular size is critical for the degree of viscosity and flexibility of the hyaluronic acid to modify in the reaction vessel for crosslinking properties during the preparation of the gel and its effect on adhesion, survival, proliferation, and differentiation of transplanted progenitor cells. Several key points need further consideration. (1) In this study, staining positively for 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindo-carbocyanine-labeled acetylated low-density lipoprotein and vascular endothelial growth factor 2 (VEGFR2) were used, which can promote angiogenesis. To determine potential paracrine effect in the induction of angiogenesis, it would be informative to examine whether these cells were positive for stem cell antigen-1 and CD45
À to differentiate between hematopoietic and nonhematopoietic progenitor cells and whether the cells were CD133 The findings from such studies could be important in the development of better hydrogel biomaterials for regeneration of myocardium after infarction. When examined through the lens of the clinical practitioner dealing with ischemic heart disease, several questions come to mind. The described model delivers the EPCs at the time of infarct. In clinical practice, this may not always be possible. Would delivery of the shearthinning hydrogel containing EPCs in a delayed time frame yield the same beneficial effects? The animals were killed 4 weeks after the infarct. Would the beneficial effect have been durable if they had been observed for a longer period? Can the shear-thinning hydrogel containing EPCs be delivered through a less invasive approach with equal effect?
The cardiac surgeon encounters patients with ischemic cardiomyopathy who are often treated with coronary artery revascularization or, in more advanced stages, mechanical circulatory support in the form of left ventricular assist devices. These therapies lead to varying degrees of myocardial recovery, particularly in the setting of viable but ischemic myocardium. Would there be a role for therapies with shear-thinning hydrogel containing EPCs in conjunction with such more conventional surgery? The possibilities are certainly tantalizing, but in reality this remains a distant goal.
CONCLUSIONS
Clearly, the findings in the rat model support improved cardiac function after ischemia treated with injections of shear-thinning hydrogel containing EPCs. Although these results are promising they need to be reproduced in a more clinically relevant model, such as swine, with anatomy and pathophysiology more akin to humans, to warrant extension into human trials. In addition, more detailed mechanistic investigations are required, along with demonstrations of durability of effect. Nevertheless, the use of injectable shear-thinning hydrogel containing EPCs in myocardial regeneration opens new opportunities to develop better biomaterials for therapeutic efficacy of cell therapy in cardiovascular diseases. The investigations on the factors involved in such a beneficial effect and the underlying cellular and molecular mechanisms could identify novel molecules and targets that could be used to prepare protein-engineered hydrogels for improved efficacy in tissue engineering and regenerative medicine in ischemic heart diseases.
